Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
But the Astra/Daiichi ADC stumbles in lung cancer.
The company is starting four new pivotal trials this year.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
